Infection Clinical Trial
Official title:
An Open Randomised Comparative Multicentre Study of the Efficacy, Safety and Toleration of Voriconazole Versus Amphotericin-B in the Treatment of Acute Invasive Aspergillosis in Immunocompromised Patients
RATIONALE: Antifungal therapy with voriconazole or amphotericin B may be an effective
treatment for aspergillosis. It is not yet known whether voriconazole is more effective than
amphotericin B in treating patients with aspergillosis.
PURPOSE: Randomized phase III trial to compare the effectiveness of voriconazole with
amphotericin B in treating patients with aspergillosis.
OBJECTIVES: I. Compare the efficacy, safety, and toleration of voriconazole versus
amphotericin B (CAB) in the treatment of acute invasive aspergillosis in immunocompromised
patients. II. Compare the efficacy, safety, and toleration of voriconazole versus CAB
followed by other antifungal therapy in the treatment of acute invasive aspergillosis in
immunocompromised patients. III. Compare survival in patients treated with voriconazole
versus CAB with or without other antifungal therapy. IV. Investigate resource utilization in
patients treated with voriconazole versus CAB with or without other antifungal therapy.
OUTLINE: This is an open label, randomized, multicenter study. Patients are stratified
according to center, site of infection, underlying disease, and baseline neutrophil count.
Patients are randomized to one of two treatment arms. Arm I: Patients receive voriconazole
IV every 12 hours for 7-28 days and continue with oral voriconazole twice a day for a
maximum total duration of 12 weeks of therapy. Arm II: Patients receive intravenous
amphotericin B daily for at least 2 weeks; treatment continues for a maximum of 12 weeks.
Patients discontinued from study drug treatment because of toxicity, intolerance or clinical
failure may receive alternative (nonstudy) antifungal therapy. All patients are monitored
for a total of 16 weeks.
PROJECTED ACCRUAL: A sufficient number of patients will be accrued so that 212 patients (106
per study arm) will be eligible for the study.
;
Allocation: Randomized, Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04529421 -
Assocation Between In-person Instruction and COVID-19 Risk
|
||
Recruiting |
NCT04081792 -
Optimal Antibiotics for Operated Diabetic Foot Infections
|
N/A | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Recruiting |
NCT04674657 -
Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
|
||
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Recruiting |
NCT00342589 -
New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia
|
||
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Completed |
NCT03296423 -
Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly
|
Phase 4 | |
Withdrawn |
NCT04217252 -
Clinical Application of High-throughput Sequencing Technology for the Diagnosis of Patients With Severe Infection
|
N/A | |
Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
Recruiting |
NCT02905552 -
Myelodysplasic Syndromes and Risk Factors for Infection
|
N/A | |
Withdrawn |
NCT02904434 -
Gastrointestinal Implications of Voriconazole Exposure
|
||
Active, not recruiting |
NCT02768454 -
Antimicrobials Stewardship by Pharmacist
|
N/A | |
Completed |
NCT02219776 -
Decreasing Infection In Arthroscopic Shoulder Surgery
|
N/A | |
Completed |
NCT02210169 -
RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates
|
N/A | |
Recruiting |
NCT02098226 -
Evaluation of MALDI Biotyper CA System for Detection of Gram- and Gram+ Bacteria and Yeasts
|
N/A | |
Completed |
NCT01846832 -
A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection
|
Phase 3 | |
Terminated |
NCT01441206 -
Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants
|
Phase 1 | |
Completed |
NCT01434797 -
Value of PET/CT Imaging in the Diagnosis of Permanent Central Venous Catheters Infection
|
||
Completed |
NCT01159834 -
Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)
|
N/A |